AstraZeneca, Amgen Breathing Easier with Optimistic Phase III Asthma Drug Results

After announcing a successful primary endpoint in November, AstraZeneca and Amgen presented the full data on their severe asthma antibody candidate on Friday.

The Phase III double-blinded trial, NAVIGATOR, showed the duo’s potentially first-in-class medicine tezepelumab to significantly reduce the annual asthma exacerbation rate (AAER) in severe, uncontrolled asthma patients.